Predicting Infection Risk in Rheumatoid Arthritis Patients Treated with Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs: An Application of Machine Learning
Studies in Health Technology and Informatics · 2025
DOI: 10.3233/shti251271 ↗Kurz gefasst
Fachartikel in der Zeitschrift Studies in Health Technology and Informatics, 2025. Verfasst von Kuan Peng und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Machine Learning, Antirheumatic Agents, Biological Products. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Patients with rheumatoid arthritis (RA) on biologic or targeted synthetic DMARDs (b/ts DMARDs) face increased serious infection risk. This study developed and validated a machine learning model to predict one-year risk using data from Hong Kong’s CDARS and the U.S. All of Us database. Among 3,159 CDARS and 1,845 All of Us patients, AUROCs were 0.840 and 0.729. Key predictors included prior infections, diabetes, DMARD type, and inflammatory markers. Rituximab posed the highest risk. The model supports personalized RA treatment and infection prevention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
- School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
- Population Health Data Center, National Cheng Kung University, Tainan, Taiwan.
- HKU Musketeers Foundation Institute of Data Science, The University of Hong Kong, Hong Kong SAR, China.
- Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, SA, Australia.
Zitieren
APA
Peng, K., Yang, D., Wang, J., Shen, C. Y., Cheng, M. C., Chan, S. C. W., Tang, I. Y. K., Zhang, Q., Lai, E. C., Pratt, N. L., Wong, I. C. K., Lau, C. S., Guo, J. J., & Li, X. (2025). Predicting Infection Risk in Rheumatoid Arthritis Patients Treated with Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs: An Application of Machine Learning. Studies in Health Technology and Informatics. https://doi.org/10.3233/shti251271
Vancouver
Peng K, Yang D, Wang J, Shen CY, Cheng MC, Chan SCW, et al. Predicting Infection Risk in Rheumatoid Arthritis Patients Treated with Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs: An Application of Machine Learning. Studies in Health Technology and Informatics. 2025. doi:10.3233/shti251271
BibTeX
@article{Peng2025,
author = {Peng, Kuan and Yang, Deliang and Wang, Jiaqi and Shen, Chin-Yao and Cheng, Michael Chun-Yuan and Chan, Shirley C W and Tang, Iris Y K and Zhang, Qingpeng and Lai, Edward Chia-Cheng and Pratt, Nicole L and Wong, Ian Chi Kei and Lau, Chak-Sing and Guo, Jeff Jianfei and Li, Xue},
title = {Predicting Infection Risk in Rheumatoid Arthritis Patients Treated with Biological and Targeted Synthetic Disease-Modifying Anti-Rheumatic Drugs: An Application of Machine Learning},
journal = {Studies in Health Technology and Informatics},
year = {2025},
doi = {10.3233/shti251271}
}
EUVIMED